The Importance of a Multidisciplinary Team in Building Bladder Cancer Guidelines
BY Jeffrey Holzbeierlein, M.D.
Jeffrey Holzbeierlein, M.D., University of Kansas Medical Center, discusses how important it was that a multidisciplinary team came together to create the non-metastatic muscle-invasive bladder cancer guidelines.
Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines
BY Johnathan E. Rosenberg, M.D.
Jonathan E. Rosenberg, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Diane Zipursky Quale on Shared Decision Making for Bladder Cancer
BY Diane Zipursky Quale
Diane Zipursky Quale, co-founder of the Bladder Cancer Advocacy Network, discusses the importance of patients discussing their treatment options with their physician before undergoing surgery.
Frontline Keytruda Shows Benefit Bladder Cancer
BY Jason Harris
For patients with cisplatin-ineligible advanced urothelial cancer, frontline treatment with Keytruda (pembrolizumab) showed long-lasting response, according to updated phase 2 results from the KEYNOTE-052 trial.
Expert Discusses Urothelial Carcinoma's Newest Agent
BY Shannon Connelly
Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.
Pre-Surgical Gemcitabine Plus Cisplatin Benefits Bladder Cancer
BY Ariela Katz
When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.
Combined Modality Treatment May Be OK as First Course of Treatment for Muscle-Invasive Bladder Cancer
BY Katie Kosko
Combined modality treatment (CMT) could be considered a first course of treatment for patients with muscle-invasive bladder cancer, according to the authors of a recent study published in the International Journal of Radiation Oncology.
Drug Combination Is Effective in Urothelial Carcinoma
BY Jason M. Broderick
When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
Combination Improves Progression-Free Survival in Urothelial Carcinoma
BY Jason Harris
According to results from the phase 3 RANGE trial, the addition of Cyramza (ramucirumab) to docetaxel resulted in improved progression-free survival for patients with previously treated locally advanced or unresectable or metastatic urothelial carcinoma.
Marilu Henner: Acknowledging Symptoms is the First Stop on the Road to Health
BY Brielle Urciuoli
Actress Marilu Henner spoke with CURE about her husband's journey with cancer and the importance of having the difficult conversations.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Bladder CURE discussion group.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Bladder Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of bladder cancer.
Gallbladder Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of gallbladder cancer.